Health

Most patients using weight-loss drugs like Wegovy stop within a year, data show

11 July 2023, 5:39 pm 1 minute

Reuters exclusively reported that Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s (NOVOb.CO) Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply.

Market Impact

Shares of the Danish drugmaker fell 2.3% on Tuesday.

Article Tags

Topics of Interest: Health

Type: Reuters Best

Sectors: Pharmaceuticals & Healthcare

Regions: Americas

Countries: United States

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

Share this article

Work Email Address *

Country *

I'd like to receive communications about Reuters resources, events, products, or services.

(Please note you can manage and update your preferences at any time.) By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement.

By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field

Work Email Address *

Country *

More of Reuters Best

Shein IPO: UK regulator decision slowed by NGO challenge

Most patients using weight-loss drugs like Wegovy stop within a year, data show

Market Impact

More of Reuters Best

Shein IPO: UK regulator decision slowed by NGO challenge

Rosneft, Reliance agree biggest ever India-Russia oil supply deal

China bans export of critical minerals to US as trade tensions escalate

Internal transactions at food giant ADM spark a sprawling criminal probe